SecBot SecBot
6-K ·Filed Aug 10, 2026

DRTS

Alpha Tau Medical Ltd.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001213900-26-086947
Notable filing: 6-K
Actionable Insight • Neutral

The dual-listing is a liquidity-enhancing move but does not change fundamentals or raise capital. Monitor for increased trading volumes and potential index inclusion in Israeli benchmarks, but no immediate catalyst for the stock price on Nasdaq. The company remains pre-commercialization with no approved product, so focus should remain on clinical trial milestones and regulatory progress.

DirectionNeutral
Confidencemedium
Horizonweeks

Alpha DaRT

▲ Bullish Named in this 6-K
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.60
T+0 close · Aug 10, 2026 · via day close
Latest settled
−0.44%
T+60 · $13.54
Vs SPY
+1.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $13.60entry
  2. T+1 · 3mo ago +4.93%α +5.25% · $14.27
  3. T+5 · 3mo ago +4.04%α +4.09% · $14.15
  4. T+20 · 2mo ago +9.12%α +10.03% · $14.84
  5. T+60 · 14d ago −0.44%α +1.98% · $13.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) while maintaining its Nasdaq listing. The company registered all outstanding shares (92,478,154) plus potential future issuances from warrants, options, RSUs, and employee plans for TASE trading. This listing broadens the shareholder base and provides Israeli investors access in local currency and hours, but does not involve raising new capital or changing the Nasdaq status.

Key Facts

  • Alpha Tau intends to dual-list on Tel Aviv Stock Exchange (TASE) alongside existing Nasdaq listing.
  • Registered shares include 92,478,154 outstanding ordinary shares; up to 36,733,096 shares underlying existing convertible securities (warrants, options, RSUs); up to 12,889,753 from authorized but unissued options; and up to 4,257,358 from the employee share purchase plan.
  • No new capital raising or change in Nasdaq listing status involved.
  • Shares will trade on TASE under symbol DRTS (English) and a Hebrew symbol.
  • Alpha DaRT treatment is not yet approved for commercial use outside clinical trials.

Financial Impact

No financial figures disclosed; dual-listing does not involve new capital raise or immediate dilution.

Risk Factors

  • Dual-listing does not address the lack of approved commercial product or potential clinical trial setbacks.
  • Potential for increased administrative costs and regulatory compliance burden from operating on two exchanges.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-086947
Document: ea030130901ex99-1.htm0001213900-26-086947
Document: 0001213900-26-086947-index-headers.html0001213900-26-086947
Document: 0001213900-26-086947-index.html0001213900-26-086947
Document: 0001213900-26-086947.txt0001213900-26-086947

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026